Dihexa

WHAT IT IS

Dihexa is not a peptide in the strict sense of a natural amino-acid chain, but a peptidomimetic, a small synthetic molecule engineered to be metabolically stable and orally active while mimicking part of an angiotensin IV-derived peptide fragment.

It was developed by Joseph Harding's laboratory at Washington State University, originally described in a 2013 paper reporting oral activity and blood-brain-barrier penetration not seen in earlier angiotensin IV analogs.

It is sold as a research chemical and has never advanced through any registered human clinical trial program.

FDA status: Dihexa is not FDA-approved for any indication and has not been evaluated by the FDA in human trials; the FDA has stated it has no human exposure data for the compound.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published preclinical work, entirely in animal and cell models, has examined:

• Reversal of drug-induced and age-related memory deficits in rats
• Promotion of dendritic spine formation and synaptogenesis in neuronal cell models
• Proposed activation of the hepatocyte growth factor receptor, c-Met, as a signaling pathway for its neurotrophic effects
• Potential relevance to Alzheimer's-type cognitive decline models in rodents

PROPOSED BIOLOGICAL MECHANISMS

Dihexa's developers proposed that it works by activating the hepatocyte growth factor and c-Met receptor system, a pathway with known roles in neuronal growth and synaptic plasticity, positioning it as an unusually potent synaptogenic agent relative to naturally occurring growth factors.

That mechanism case relied heavily on a small number of papers from the same laboratory. Two of the most cited of those papers, a 2014 paper on HGF/c-Met dependence and a related 2012 analog-development paper, were retracted by the Journal of Pharmacology and Experimental Therapeutics in April 2025 after Washington State University's investigation found falsified or fabricated data in key figures [1](https://pubmed.ncbi.nlm.nih.gov/25187433/) [2](https://www.jpet.org/content/393/1/100327).

The foundational 2013 paper first describing Dihexa's synthesis and oral activity has separately carried a publisher expression of concern since 2021, predating the 2025 retractions.

With those papers retracted, the published mechanistic case connecting Dihexa specifically to HGF/c-Met activation is substantially weaker than earlier marketing and secondary summaries of the compound have suggested.

AREAS OF RESEARCH INTEREST

• Whether any of Dihexa's reported procognitive effects in rodents can be confirmed by independent laboratories using verified, unretracted data
• What the actual mechanism of action is, now that key papers supporting the HGF/c-Met explanation have been retracted
• Whether the compound has ever undergone controlled human safety testing, which to date it has not
• How the research-integrity findings at the originating laboratory should affect confidence in the broader Dihexa literature, including papers not directly retracted

WHAT THE EVIDENCE CURRENTLY SUGGESTS

All available efficacy data on Dihexa comes from animal studies, primarily rodent models of memory and synaptic plasticity, conducted by a small number of affiliated researchers.

No human clinical trial data exists in the peer-reviewed literature or public trial registries for Dihexa.

The 2025 retraction of two central mechanism papers, following an earlier expression of concern on the foundational synthesis paper, materially undermines the strength of the published case for how and how well Dihexa is claimed to work [3](https://www.peptidesdossier.com/research/jpet-2025-dihexa-retraction-landscape).